Weiss Ratings Reaffirms Hold (C) Rating for Integer (NYSE:ITGR)

Integer (NYSE:ITGR - Get Free Report)'s stock had its "hold (c)" rating reaffirmed by Weiss Ratings in a note issued to investors on Wednesday,Weiss Ratings reports.

A number of other equities research analysts have also issued reports on ITGR. Truist Financial cut their price target on Integer from $145.00 to $137.00 and set a "buy" rating for the company in a research note on Friday, July 25th. Raymond James Financial cut their price target on Integer from $150.00 to $143.00 and set an "outperform" rating for the company in a research note on Friday, July 25th. Wells Fargo & Company cut their price target on Integer from $152.00 to $132.00 and set an "overweight" rating for the company in a research note on Friday, July 25th. Finally, Wall Street Zen upgraded Integer from a "hold" rating to a "buy" rating in a research note on Saturday, August 30th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $139.57.

Integer Stock Up 1.5%

Shares of ITGR stock opened at $105.32 on Wednesday. Integer has a 12 month low of $99.73 and a 12 month high of $146.36. The stock has a market cap of $3.69 billion, a P/E ratio of 46.40, a P/E/G ratio of 0.82 and a beta of 0.97. The company has a current ratio of 3.41, a quick ratio of 2.18 and a debt-to-equity ratio of 0.72. The company has a 50 day simple moving average of $105.41 and a two-hundred day simple moving average of $113.83.

Integer (NYSE:ITGR - Get Free Report) last announced its quarterly earnings data on Thursday, July 24th. The medical equipment provider reported $1.55 EPS for the quarter, missing the consensus estimate of $1.57 by ($0.02). The firm had revenue of $476.00 million for the quarter, compared to the consensus estimate of $464.37 million. Integer had a net margin of 4.61% and a return on equity of 12.27%. The firm's revenue for the quarter was up 11.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.30 earnings per share. Integer has set its FY 2025 guidance at 6.250-6.510 EPS. On average, research analysts expect that Integer will post 6.01 earnings per share for the current year.

Hedge Funds Weigh In On Integer

Institutional investors have recently bought and sold shares of the stock. Opal Wealth Advisors LLC purchased a new position in Integer during the first quarter valued at $28,000. SVB Wealth LLC bought a new stake in shares of Integer in the 1st quarter worth about $35,000. Bessemer Group Inc. increased its holdings in shares of Integer by 73.1% in the 1st quarter. Bessemer Group Inc. now owns 296 shares of the medical equipment provider's stock worth $35,000 after buying an additional 125 shares during the last quarter. CWM LLC increased its holdings in shares of Integer by 46.1% in the 2nd quarter. CWM LLC now owns 355 shares of the medical equipment provider's stock worth $44,000 after buying an additional 112 shares during the last quarter. Finally, MAI Capital Management increased its holdings in shares of Integer by 220.9% in the 2nd quarter. MAI Capital Management now owns 369 shares of the medical equipment provider's stock worth $45,000 after buying an additional 254 shares during the last quarter. 99.29% of the stock is owned by hedge funds and other institutional investors.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.